ArticleCommunications medicine2026
Analysis of a PCORnet
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough New York City (NYC) is a hotspot for hepatitis delta virus (HDV) in the United States (US), the epidemiology of HDV remains poorly understood. We aimed to determine HDV testing and positivity rates, calculate prevalence of liver disease progression by HDV status, and assess the association between HDV and community resources.
methodsWe utilized the INSIGHT database, which contains data from the five major NYC health systems, to identify adults with laboratory and/or diagnosis code evidence of hepatitis B virus (HBV) from 2010-2023. HDV positivity included HDV RNA ≥ 20 IU/mL and/or positive results for HDV Ab, RNA, and Ag. Prevalence of liver-related complications was calculated. Community deprivation index was used to evaluate socioeconomic disparities by HDV testing and positivity status.
resultsHere we show that among 106,210 patients with HBV, 5,388 (5.1%) have received HDV testing; 294 (5.5%) are HDV + . HDV-tested individuals are more likely to be older and Asian, receive comprehensive HBV care, and have more community resources. HDV+ individuals are more likely to be female, White, and have higher prevalence of liver disease progression.
conclusionsHDV is undertested and under-detected, even in a high-prevalence US region. Early linkage to treatment is essential given high rates of liver disease progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.